Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background—: In comparison with men, women have a better prognosis when experiencing aortic valve stenosis, hypertrophic cardiomyopathy, or heart failure. Recent data suggest that androgens like testosterone or the more potent dihydrotestosterone contribute to the development of cardiac hypertrophy and failure. Therefore, we analyzed whether antiandrogenic therapy with finasteride, which inhibits the generation of dihydrotestosterone by the enzyme 5-α-reductase, improves pathological ventricular remodeling and heart failure. Methods and Results—: We found a strongly induced expression of all 3 isoforms of the 5-α-reductase (Srd5a1 to Srd5a3) in human and mouse hearts with pathological hypertrophy, which was associated with increased myocardial accumulation of dihydrotestosterone. Starting 1 week after the induction of pressure overload by transaortic constriction, mice were treated with finasteride for 2 weeks. Cardiac function, hypertrophy, dilation, and fibrosis were markedly improved in response to finasteride treatment in not only male, but also in female mice. In addition, finasteride also very effectively improved cardiac function and mortality after long-term pressure overload and prevented disease progression in cardiomyopathic mice with myocardial Gαq overexpression. Mechanistically, finasteride, by decreasing dihydrotestosterone, potently inhibited hypertrophy and Akt-dependent prohypertrophic signaling in isolated cardiac myocytes, whereas the introduction of constitutively active Akt blunted these effects of finasteride. Conclusions—: Finasteride, which is currently used in patients to treat prostate disease, potently reverses pathological cardiac hypertrophy and dysfunction in mice and might be a therapeutic option for heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Non-genomic actions of androgens
Foradori, C. D., Weiser, M. J., & Handa, R. J. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2007.10.005 · Cited by 493
Cantagrel, V., Lefeber, D. J., Ng, B. G., Guan, Z., Silhavy, J. L., Bielas, S. L., Lehle, L., Hombauer, H., Adamowicz, M., Swiezewska, E., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.001 · Cited by 309 · cited 1×
“is converted to DHT by isoforms 1 to 3 (Srd5a1–Srd5a3) of the 5-α-reductase, whereas Srd5a3 is also involved in N-linked protein glycosylation.(14,24,25) Each of the 3 enzymes is expressed”
BackgroundNovel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer
Uemura, M., Tamura, K., Chung, S., Honma, S., Okuyama, A., Nakamura, Y., & Nakagawa, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00656.x · Cited by 263
Vicencio, J. M., Ibarra, C., Estrada, M., Chiong, M., Soto, D., Parra, V., Diaz-Araya, G., Jaimovich, E., & Lavandero, S. (2006) · Endocrinology · doi:10.1210/en.2005-1139 · Cited by 149 · cited 1×
“Testosterone-dependent activation of cytosolic signaling molecules such as Akt, ERK, and mTOR and its contribution to androgen-induced hypertrophy has been suggested previously.(40,41) The impact of androgens on cellular signaling pathways is thought to occur within their nongenomic mode of action: instead of operatin…”
BackgroundLuczak, E. D., & Leinwand, L. A. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163156 · Cited by 143 · cited 1×
“Women with heart failure have a lower mortality than men and also a better prognosis when experiencing hypertension, aortic valve stenosis, or hypertrophic cardiomyopathy.(1,5) Sex hormones might account for these differences, and, indeed, the expression of androgen, and estrogen receptors was found in male and female…”
BackgroundBorst, S. E., Yarrow, J. F., Conover, C. F., Nseyo, U., Meuleman, J. R., Lipinska, J. A., Braith, R. W., Beck, D. T., Martin, J. S., Morrow, M., et al. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00592.2013 · Cited by 98 · cited 1×
“DHT effects on the prostate as a consequence of finasteride administration.(38)”
BackgroundReduced Bone Mass and Muscle Strength in Male 5α-Reductase Type 1 Inactivated Mice
Windahl, S. H., Andersson, N., Börjesson, A. E., Swanson, C., Svensson, J., Movérare-Skrtic, S., Sjögren, K., Shao, R., Lagerquist, M. K., & Ohlsson, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021402 · Cited by 56 · cited 2×
“DHT, the most potent endogenous androgen, has a 2- to 5-fold higher binding capacity to the androgen receptor and a 10-fold higher potency to induce androgen receptor–mediated signaling than testosterone.14 As a consequence, the main physiological function of DHT seems to be the amplification of testosterone-mediated…”
Background
Cited by
Physiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887
Mechanistic Pathways of Sex Differences in Cardiovascular Disease
Regitz-Zagrosek, V., & Kararigas, G. (2017) · Physiological Reviews · doi:10.1152/physrev.00021.2015 · Cited by 732
Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer
Ben-Batalla, I., Vargas-Delgado, M. E., von Amsberg, G., Janning, M., & Loges, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01184 · Cited by 149
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Salem, J.-E., Nguyen, L. S., Hammoudi, N., Preud'homme, G., Hulot, J.-S., Leban, M., Funck-Brentano, C., Touraine, P., Isnard, R., Bachelot, A., et al. (2018) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2017.10.017 · Cited by 17
“[39] It was suggested that lower levels of androgens in women might explain why they have a better prognosis when experiencing aortic valve stenosis, hypertrophic cardiomyopathy, or heart failure, in comparison to men.”
BackgroundResult
Metadata
- Authors
- Zwadlo, C., Schmidtmann, E., Szaroszyk, M., Kattih, B., Froese, N., Hinz, H., Schmitto, J. D., Widder, J., Batkai, S., Bähre, H., Kaever, V., Thum, T., Bauersachs, J., & Heineke, J.
- Venue
- Circulation
- Published
- 2015-03-24
- Volume
- 131
- Issue
- 12
- Pages
- 1071-1081
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1969070604
- Cited by
- 74
- References
- 8
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction. https://app.cochat.ai/papers/10.1161/circulationaha.114.012066
- The paper
- Zwadlo, C., Schmidtmann, E., Szaroszyk, M., Kattih, B., Froese, N., Hinz, H., Schmitto, J. D., Widder, J., Batkai, S., Bähre, H., Kaever, V., Thum, T., Bauersachs, J., & Heineke, J. (2015). Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction. Circulation. https://doi.org/10.1161/circulationaha.114.012066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.